Shopping Cart
- Remove All
Your shopping cart is currently empty
SRI 31215 TFA
🥰Excellent
Catalog No. T5478Cas No. 1832686-44-8
SRI 31215 TFA, a small molecule that acts as a triplex inhibitor of matriptase, hepsin and HGFA and mimics the activity of HAI-1/2, endogenous inhibitors of HGF activation with IC50s of 0.69 μM, 0.65 μM, 0.3 μM,
SRI 31215 TFA
🥰Excellent
Purity: 99.97%
Catalog No. T5478Cas No. 1832686-44-8
SRI 31215 TFA, a small molecule that acts as a triplex inhibitor of matriptase, hepsin and HGFA and mimics the activity of HAI-1/2, endogenous inhibitors of HGF activation with IC50s of 0.69 μM, 0.65 μM, 0.3 μM,
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $36 | In Stock | |
| 5 mg | $88 | In Stock | |
| 10 mg | $137 | In Stock | |
| 25 mg | $275 | In Stock | |
| 50 mg | $412 | In Stock | |
| 100 mg | $586 | In Stock | |
| 200 mg | $793 | In Stock | |
| 1 mL x 10 mM (in DMSO) | $103 | In Stock |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "SRI 31215 TFA"
Capmatinib xHCl
INCB28060, INC280, Capmatinib hydrochloride(free base)
T84161029714-89-3
Capmatinib xHCl (INCB28060) is a potent, orally active, selective, and ATP competitive c-Met kinase inhibitor, potently blocking in vitro kinase activity (IC50 = 0.13 nM) as well as constitutive or HGF-stimulated activity in cells (IC50 values range from 0.3 to 1.1 nM).
- $37
Size
QTY
BMS 777607
Cited
BMS-777607, BMS777607, BMS 817378
T26991025720-94-8
BMS 777607 (BMS 817378) is a Met-related inhibitor targeting c-Met, Axl, Ron, and Tyro3 with IC50 values of 3.9 nM, 1.1 nM, 1.8 nM, and 4.3 nM, respectively. BMS-777607 has been investigated in basic science research for malignant solid tumors.
- $30
Size
QTY
CitedNorcantharidin Cited
Norcantharadine, Endothall anhydride
T28945442-12-6
Norcantharidin (Norcantharadine) is a synthetic anticancer compound which is a dual inhibitor for c-Met and EGFR in human colon cancers.
- $50
Size
QTY
CitedAmuvatinib Cited
MP470, HPK 56
T2516850879-09-3
Amuvatinib (MP470) is an orally bioavailable synthetic carbothioamide with potential antineoplastic activity.
- $44
Size
QTY
CitedCabozantinib S-malate
XL184, Cabozantinib Malate, Cabozantinib
T17971140909-48-3
Cabozantinib S-malate (XL184) is the s-malate salt form of cabozantinib, an orally bioavailable, small molecule receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity.
- $40
Size
QTY
Bacitracin Zinc
Zinc bacitracin, Bacitracin zinc salt
T22081405-89-6
Bacitracin Zinc is an antibiotic that interferes with the dephosphorylation of C55-isoprenyl pyrophosphate, interference for inhibition of cleavage of Tyr from Met-enkephalin(IC50=10 μM).
- $36
Size
QTY
L-Ascorbic acid 2-phosphate trisodium Cited
Sodium L-ascorbyl-2-phosphate, Sodium ascorbyl phosphate, Sodium ascorbyl monophosphate, L-Ascorbic acid 2-phosphate trisodium salt, 2-Phospho-L-ascorbic acid trisodium salt
T218566170-10-3
L-Ascorbic acid 2-phosphate trisodium (Sodium ascorbyl phosphate) is utilized in biocatalytic dephosphorylation for electric power generation and electrochemical detection assays.
- $42
Size
QTY
Cited(±)-Norcantharidin
Norcantharidin, Endothall anhydride
T565629745-04-8
(±)-Norcantharidin (Endothall anhydride) is a synthetic anticancer compound which is a dual inhibitor for c-Met and EGFR in human colon cancers.
- $37
Size
QTY
Crizotinib Cited
PF-02341066
T1661877399-52-5
Crizotinib (PF-02341066) is an ATP-competitive small-molecule tyrosine kinase inhibitor of c-MET (IC50: 8 nM) and ALK (IC50: 20 nM) receptors.
- $46
Size
QTY
CitedCapmatinib 2HCl
INCB28060 2HCl, INC-280 2HCl
T42601197376-85-4
Capmatinib 2HCl (INC-280 2HCl) is a novel, ATP-competitive inhibitor of c-MET kinase with an IC50 with 0.13 nM.Capmatinib 2HCl exhibits picomolar enzymatic potency and is highly specific for c-MET with more than 10, 000-fold selectivity over a large panel of human kinases. This inhibitor potently blocks c-MET phosphorylation and activation of its key downstream effectors in c-MET-dependent tumor cell lines. As a result, Capmatinib 2HCl potently inhibits c-MET-dependent tumor cell proliferation and migration and effectively induces apoptosis in vitro.
- $37
Size
QTY
Capmatinib Cited
NVP-INC280, INCB28060, INC-280
T19631029712-80-8
Capmatinib (INCB28060) is an orally bioavailable inhibitor of the proto-oncogene c-Met (HGFR)with potential antineoplastic activity.
- $43
Size
QTY
CitedAMG-458
AMG 458
T6378913376-83-7In house
AMG-458 is a potent c-Met inhibitor with Ki of 1.2 nM, ~350-fold selectivity for c-Met than VEGFR2 in cells.
- $35
Size
QTY
Select Batch
Purity:99.97%
Contact us for more batch information
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.Product Introduction
Bioactivity
Chemical Properties
| Description | SRI 31215 TFA, a small molecule that acts as a triplex inhibitor of matriptase, hepsin and HGFA and mimics the activity of HAI-1/2, endogenous inhibitors of HGF activation with IC50s of 0.69 μM, 0.65 μM, 0.3 μM, |
| Targets&IC50 | Hepsin:0.65 μM , HGFA:0.3 μM, Matriptase:0.69 μM |
| In vitro | SRI 31215 inhibits fibroblast-induced MET activation, epithelial-mesenchymal transition and migration of cancer cells.?SRI 31215 overcomes primary resistance to cetuximab and gefitinib in HGF-producing colon cancer cells and prevents fibroblast-mediated resistance to EGFR inhibitors.?Thus, SRI 31215 blocks signaling between cancer cells and fibroblasts and inhibits the tumor-promoting activity of cancer-associated fibroblasts. |
| Cell Research | DU145 cells were cultured in 6-well tissue culture plates at a density of 1 103 cells per well.?After colonies formed (6-8 days), cells were serum-starved overnight and were then treated with recombinant HGF (10 ng/ml) or with conditioned media from 18Co fibroblasts in the presence or absence of SRI 31215 (10 μM) or the MET kinase inhibitor JNJ 38877605 (1 μM) for 24 hours.?Cells were washed with PBS and colonies were fixed and stained with 0.5% crystal violet solution in 6% glutaraldehyde. |
| Molecular Weight | 533.6 |
| Formula | C27H34F3N5O3 |
| Cas No. | 1832686-44-8 |
| Smiles | OC(=O)C(F)(F)F.CC1CN(CC2CCN(Cc3ccccc3)CC2)C(=O)N(C1)c1cccc(c1)C(N)=N |
| Relative Density. | no data available |
Storage & Solubility Information
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||
| Solubility Information | DMSO: 25 mg/mL (46.85 mM), Sonication is recommended.  | |||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy SRI 31215 TFA | purchase SRI 31215 TFA | SRI 31215 TFA cost | order SRI 31215 TFA | SRI 31215 TFA chemical structure | SRI 31215 TFA in vitro | SRI 31215 TFA formula | SRI 31215 TFA molecular weight
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.